Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...
Clinical trial approval / initiation
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...
Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial
China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...
ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors
China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...
Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101
Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval to Test SHR-1681 in Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from...
CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...
CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support
CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study...
Joincare Pharmaceutical’s JKN2403 Gains NMPA Approval for COPD Clinical Trials
China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category...
AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine
AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...
AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...
Chengdu Kanghua Biological Receives NMPA Approval for Recombinant Norovirus Vaccine
Chengdu Kanghua Biological Products Co., Ltd, (SHE: 300841), a leading biopharmaceutical company based in China,...
Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1501 Combo in Bladder Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...